Select therapeutic use:
Indications for SIMPONI ARIA:
Moderately-to-severely active rheumatoid arthritis (RA), in combination with methotrexate (MTX).
Infuse over 30 mins. 2mg/kg IV at Weeks 0 and 4, then every 8 weeks thereafter. Corticosteroids, non-biologic DMARDs, and/or NSAIDs may be continued during treatment.
<18yrs: not established.
Increased risk of serious or fatal infections (eg, TB, bacterial sepsis, viral, invasive fungal [treat empirically if develops], or other pathogens). Active infections: do not initiate therapy. Chronic or history of recurring or opportunistic infections. Conditions that predispose to infection. Travel to, or residence in, areas with endemic TB or mycoses. Test/treat latent TB and HBV infection prior to initiating therapy. Monitor closely if new infection, active TB (even if initial latent test is negative), reactivation of HBV, or blood dyscrasias occurs; discontinue if serious or opportunistic infection, sepsis, HBV reactivation, new or worsening CHF, hematological abnormality (eg, cytopenias), lupus-like syndrome, or serious hypersensitivity reaction develops. Malignancies. Perform periodic skin exams (esp. those with skin cancer risk factors). CHF (monitor). Immunosuppression. CNS demyelinating disorders. Elderly. Infants (see Interactions). Pregnancy (Cat.B). Nursing mothers: not recommended.
Concurrent abatacept, anakinra, live vaccines, therapeutic infectious agents, or other TNF blockers: not recommended. Infants exposed to golimumab in utero: do not give live vaccines for 6 months after mother’s last inj during pregnancy. Concomitant immunosuppressants (eg, corticosteroids, MTX) may increase risk of infection. Concomitant CYP450 substrates with narrow therapeutic index (eg, warfarin, cyclosporine, theophylline); monitor and may need dose adjustments of these drugs. Caution with switching between DMARDs; overlapping may further increase the risk of infection.
Upper respiratory tract infection, viral infections, bronchitis, hypertension, rash; other serious infections, malignancies (eg, melanoma, lymphoma; monitor), blood dyscrasias, new or worsening CHF, elevated liver enzymes, antibody formation.